Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	B-protein
factors	I-protein
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	B-protein
factors	I-protein
(	O
MyoD	B-protein
,	O
myogenin	B-protein
,	O
myf5	B-protein
,	O
and	O
myf6	B-protein
)	O
that	O
are	O
``	B-protein
basic	I-protein
helix-loop-helix	I-protein
''	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
promoters	B-DNA
of	O
muscle-specific	B-DNA
genes	I-DNA
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B-protein
binding	I-protein
basic	I-protein
domain	I-protein
of	O
MyoD	B-protein
confers	O
c-myc	B-DNA
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	B-protein
domains	I-protein
of	O
all	O
the	O
myogenic	B-protein
factors	I-protein
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B-protein
transcription	I-protein
factors	I-protein
.	O

Rhabdomyosarcomas	NULL
Do	NULL
Not	NULL
Contain	NULL
Mutations	NULL
in	NULL
the	NULL
DNA	NULL
Binding	NULL
Domains	NULL
of	NULL
Myogenic	NULL
Transcription	NULL
Factors	NULL
Geetha	NULL
Anand	NULL
,	NULL
*	NULL
David	NULL
N.	NULL
Shapiro	NULL
,	NULL
``	NULL
Paul	NULL
S.	NULL
Dickman	NULL
,	NULL
*	NULL
and	NULL
Edward	NULL
V.	NULL
Prochownik	NULL
**	NULL
Departments	NULL
of	NULL
*	NULL
Pediatrics	NULL
and	NULL
*	NULL
Pathology	NULL
,	NULL
Children	NULL
's	NULL
Hospital	NULL
of	NULL
Pittsburgh	NULL
,	NULL
Pittsburgh	NULL
,	NULL
Pennsylvania	NULL
15213	NULL
;	NULL
§Department	NULL
of	NULL
Molecular	NULL
Genetics	NULL
and	NULL
Biochemistry	NULL
,	NULL
University	NULL
of	NULL
Pittsburgh	NULL
Medical	NULL
Center	NULL
,	NULL
Pittsburgh	NULL
,	NULL
Pennsylvania	NULL
15261	NULL
;	NULL
and	NULL
``	NULL
Department	NULL
of	NULL
Hematology	NULL
,	NULL
St.	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hospital	NULL
,	NULL
Memphis	NULL
,	NULL
Tennessee	NULL
38101	NULL
Abstract	NULL
Skeletal	NULL
myogenesis	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
group	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
MyoD	NULL
,	NULL
myogenin	NULL
,	NULL
myfS5	NULL
,	NULL
and	NULL
myf6	NULL
)	NULL
that	NULL
are	NULL
``	NULL
basic	NULL
helix-loop-helix	NULL
``	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
promoters	NULL
of	NULL
muscle-specific	NULL
genes	NULL
and	NULL
promote	NULL
their	NULL
expression	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
after	NULL
a	NULL
mutation	NULL
of	NULL
Leu	NULL
,	NULL
,	NULL
to	NULL
Arg	NULL
the	NULL
DNA	NULL
binding	NULL
basic	NULL
domain	NULL
of	NULL
MyoD	NULL
confers	NULL
c-myc-like	NULL
functional	NULL
characteristics	NULL
to	NULL
the	NULL
protein	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
used	NULL
single-strand	NULL
conformation	NULL
polymorphism	NULL
analysis	NULL
to	NULL
determine	NULL
whether	NULL
such	NULL
mutations	NULL
occur	NULL
naturally	NULL
in	NULL
rhabdomyosarcomas	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
basic	NULL
domains	NULL
of	NULL
all	NULL
the	NULL
myogenic	NULL
factors	NULL
remain	NULL
unaltered	NULL
in	NULL
rhabdomyosarcomas	NULL
.	NULL

Selection	NULL
against	NULL
such	NULL
mutations	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
functional	NULL
redundancy	NULL
of	NULL
these	NULL
myogenic	NULL
transcription	NULL
factors	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1994	NULL
.	NULL

93:5-9	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
myogenic	NULL
proteins	NULL
«	NULL
myoD	NULL
«	NULL
SSCP	NULL
«	NULL
c-myc	NULL
»	NULL
muscle	NULL
differentiation	NULL
Introduction	NULL
MyoD	NULL
,	NULL
myogenin	NULL
,	NULL
myf5	NULL
,	NULL
and	NULL
myf6	NULL
are	NULL
a	NULL
group	NULL
of	NULL
muscle-spe-cific	NULL
,	NULL
``	NULL
basic	NULL
helix-loop-helix	NULL
``	NULL
(	NULL
bHLH	NULL
)	NULL
!	NULL

transcription	NULL
factors	NULL
that	NULL
regulate	NULL
skeletal	NULL
myogenesis	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
bind	NULL
to	NULL
the	NULL
promoters	NULL
of	NULL
many	NULL
muscle-specific	NULL
genes	NULL
at	NULL
sites	NULL
containing	NULL
the	NULL
canonical	NULL
``	NULL
E-box	NULL
``	NULL
sequence	NULL
CANNTG	NULL
.	NULL

After	NULL
binding	NULL
,	NULL
other	NULL
domains	NULL
within	NULL
these	NULL
myogenic	NULL
factors	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
adjacent	NULL
gene	NULL
(	NULL
4-7	NULL
)	NULL
.	NULL

Although	NULL
some	NULL
differences	NULL
have	NULL
been	NULL
noted	NULL
in	NULL
the	NULL
various	NULL
properties	NULL
of	NULL
these	NULL
factors	NULL
and	NULL
in	NULL
their	NULL
expression	NULL
during	NULL
embryogenesis	NULL
(	NULL
8-10	NULL
)	NULL
,	NULL
each	NULL
one	NULL
by	NULL
itself	NULL
is	NULL
fully	NULL
capable	NULL
of	NULL
inducing	NULL
myogenic	NULL
differentiation	NULL
when	NULL
expressed	NULL
ectopically	NULL
in	NULL
nonmyogenic	NULL
cells	NULL
such	NULL
as	NULL
fibroblasts	NULL
(	NULL
11	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
MyoD	NULL
,	NULL
myogenin	NULL
,	NULL
myf5	NULL
,	NULL
and	NULL
myf6	NULL
are	NULL
components	NULL
of	NULL
a	NULL
redundant	NULL
cellular	NULL
mechanism	NULL
for	NULL
ensuring	NULL
the	NULL
proper	NULL
timing	NULL
and	NULL
progression	NULL
of	NULL
skeletal	NULL
muscle	NULL
morphogenesis	NULL
.	NULL

This	NULL
concept	NULL
has	NULL
gained	NULL
support	NULL
from	NULL
recent	NULL
experiments	NULL
demonstrating	NULL
that	NULL
skeletal	NULL
muscle	NULL
development	NULL
Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Edward	NULL
V.	NULL
Prochownik	NULL
,	NULL
Division	NULL
of	NULL
Hematology	NULL
/Oncology	NULL
,	NULL
Children	NULL
's	NULL
Hospital	NULL
of	NULL
Pittsburgh	NULL
,	NULL
3705	NULL
Fifth	NULL
Avenue	NULL
at	NULL
DeSoto	NULL
,	NULL
Pittsburgh	NULL
,	NULL
PA	NULL
15213	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
5	NULL
April	NULL
1993	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
6	NULL
August	NULL
1993	NULL
.	NULL

1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
bHLH	NULL
,	NULL
basic	NULL
helix-loop-helix	NULL
;	NULL
SSCP	NULL
,	NULL
single-strand	NULL
conformation	NULL
polymorphism	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-97	NULL
-	NULL
$	NULL
2.00	NULL
Volume	NULL
93	NULL
,	NULL
January	NULL
1994	NULL
,	NULL
5-9	NULL
in	NULL
mice	NULL
lacking	NULL
functional	NULL
copies	NULL
of	NULL
MyoD	NULL
or	NULL
myf5	NULL
proceeds	NULL
relatively	NULL
normally	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
by	NULL
the	NULL
myogenic	NULL
bHLH	NULL
proteins	NULL
requires	NULL
that	NULL
they	NULL
first	NULL
dimerize	NULL
.	NULL

However	NULL
,	NULL
such	NULL
DNA	NULL
binding	NULL
by	NULL
homo-dimers	NULL
,	NULL
while	NULL
specific	NULL
,	NULL
is	NULL
relatively	NULL
weak	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Binding	NULL
is	NULL
significantly	NULL
enhanced	NULL
by	NULL
heterodimeric	NULL
association	NULL
with	NULL
the	NULL
ubiquitously	NULL
expressed	NULL
products	NULL
of	NULL
the	NULL
E2A	NULL
gene	NULL
product	NULL
(	NULL
E12	NULL
and	NULL
E47	NULL
)	NULL
and	NULL
,	NULL
indeed	NULL
,	NULL
the	NULL
active	NULL
transcriptional	NULL
complexes	NULL
in	NULL
myogenic	NULL
cells	NULL
appear	NULL
to	NULL
consist	NULL
of	NULL
such	NULL
heterodimers	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
MyoD	NULL
,	NULL
for	NULL
example	NULL
,	NULL
each	NULL
component	NULL
of	NULL
the	NULL
hetero-dimer	NULL
is	NULL
thought	NULL
to	NULL
contribute	NULL
a	NULL
DNA	NULL
half-site	NULL
recognition	NULL
specificity	NULL
such	NULL
that	NULL
the	NULL
optimal	NULL
binding	NULL
site	NULL
(	NULL
CACCTG	NULL
)	NULL
is	NULL
a	NULL
composite	NULL
of	NULL
the	NULL
preferred	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
individual	NULL
components	NULL
in	NULL
homodimeric	NULL
form	NULL
(	NULL
15	NULL
)	NULL
.	NULL

myc	NULL
family	NULL
proteins	NULL
are	NULL
also	NULL
members	NULL
of	NULL
the	NULL
bHLH	NULL
family	NULL
and	NULL
bind	NULL
the	NULL
E-box	NULL
motif	NULL
CACGTG	NULL
in	NULL
association	NULL
with	NULL
the	NULL
recently	NULL
described	NULL
protein	NULL
max	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Myogenic	NULL
differentiation	NULL
is	NULL
accompanied	NULL
by	NULL
c-myc	NULL
downregulation	NULL
and	NULL
enforced	NULL
c-myc	NULL
expression	NULL
inhibits	NULL
the	NULL
differentiation	NULL
process	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

The	NULL
myogenic	NULL
proteins	NULL
and	NULL
c-myc	NULL
can	NULL
thus	NULL
be	NULL
viewed	NULL
as	NULL
components	NULL
of	NULL
opposing	NULL
regulatory	NULL
pathways	NULL
in	NULL
which	NULL
MyoD	NULL
and	NULL
its	NULL
homologues	NULL
drive	NULL
the	NULL
differentiation	NULL
process	NULL
and	NULL
exert	NULL
an	NULL
anti-proliferative	NULL
effect	NULL
(	NULL
20	NULL
)	NULL
whereas	NULL
c-myc	NULL
inhibits	NULL
myogenic	NULL
differentiation	NULL
and	NULL
drives	NULL
proliferation	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
myogenic	NULL
and	NULL
myc	NULL
family	NULL
member	NULL
bHLH	NULL
proteins	NULL
contain	NULL
related	NULL
DNA	NULL
binding	NULL
basic	NULL
domains	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
MyoD	NULL
and	NULL
c-myc	NULL
are	NULL
identical	NULL
at	NULL
5	NULL
of	NULL
the	NULL
14	NULL
amino	NULL
acids	NULL
that	NULL
comprise	NULL
this	NULL
motif	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
reported	NULL
that	NULL
substitution	NULL
of	NULL
the	NULL
myogenically	NULL
highly	NULL
conserved	NULL
Leu	NULL
,	NULL
;	NULL
in	NULL
MyoD	NULL
with	NULL
the	NULL
similarly	NULL
conserved	NULL
Arg	NULL
residue	NULL
present	NULL
in	NULL
myc	NULL
and	NULL
max	NULL
family	NULL
members	NULL
imparts	NULL
novel	NULL
properties	NULL
to	NULL
MyoD	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
mutant	NULL
protein	NULL
retained	NULL
the	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
a	NULL
consensus	NULL
MyoD	NULL
site	NULL
,	NULL
it	NULL
was	NULL
unable	NULL
to	NULL
transactivate	NULL
a	NULL
promoter	NULL
containing	NULL
this	NULL
site	NULL
and	NULL
actually	NULL
competed	NULL
with	NULL
wild-type	NULL
MyoD	NULL
in	NULL
this	NULL
regard	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
mutant	NULL
MyoD	NULL
protein	NULL
gained	NULL
the	NULL
capacity	NULL
to	NULL
recognize	NULL
a	NULL
c-myc/	NULL
max	NULL
binding	NULL
site	NULL
and	NULL
,	NULL
like	NULL
c-myc	NULL
,	NULL
correctly	NULL
downregulated	NULL
a	NULL
gene	NULL
containing	NULL
such	NULL
a	NULL
site	NULL
.	NULL

The	NULL
acquisition	NULL
of	NULL
these	NULL
unexpected	NULL
properties	NULL
by	NULL
the	NULL
mutant	NULL
MyoD	NULL
protein	NULL
suggested	NULL
a	NULL
novel	NULL
means	NULL
by	NULL
which	NULL
skeletal	NULL
muscle	NULL
tumors	NULL
(	NULL
rhabdomyosarcomas	NULL
)	NULL
might	NULL
arise	NULL
.	NULL

Point	NULL
mutation	NULL
of	NULL
the	NULL
highly	NULL
conserved	NULL
Leu	NULL
,	NULL
;	NULL
;	NULL
,	NULL
codon	NULL
(	NULL
CTG	NULL
)	NULL
of	NULL
MyoD	NULL
to	NULL
that	NULL
encoding	NULL
an	NULL
arginine	NULL
(	NULL
CGG	NULL
)	NULL
found	NULL
at	NULL
the	NULL
analogous	NULL
position	NULL
of	NULL
the	NULL
c-myc	NULL
basic	NULL
domain	NULL
would	NULL
result	NULL
,	NULL
on	NULL
the	NULL
one	NULL
hand	NULL
,	NULL
in	NULL
a	NULL
dominant-negative	NULL
form	NULL
of	NULL
the	NULL
protein	NULL
that	NULL
would	NULL
compete	NULL
with	NULL
wild-type	NULL
myogenic	NULL
factors	NULL
and	NULL
block	NULL
their	NULL
transactivation	NULL
of	NULL
target	NULL
genes	NULL
in	NULL
myoblasts	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
mutant	NULL
MyoD	NULL
could	NULL
substitute	NULL
for	NULL
authentic	NULL
c-myc	NULL
protein	NULL
,	NULL
which	NULL
would	NULL
be	NULL
downregulated	NULL
in	NULL
cells	NULL
undergoing	NULL
terminal	NULL
myogenic	NULL
commitment	NULL
.	NULL

c-myc	NULL
target	NULL
genes	NULL
might	NULL
therefore	NULL
continue	NULL
to	NULL
be	NULL
regulated	NULL
normally	NULL
resulting	NULL
in	NULL
a	NULL
sustained	NULL
prolifera-	NULL
Basic	NULL
Domain	NULL
of	NULL
Myogenic	NULL
Factors	NULL
in	NULL
Rhabdomyosarcoma	NULL
5	NULL
tive	NULL
signal	NULL
.	NULL

This	NULL
combination	NULL
of	NULL
inhibited	NULL
differentiation	NULL
and	NULL
enhanced	NULL
proliferation	NULL
,	NULL
mediated	NULL
either	NULL
by	NULL
mutant	NULL
MyoD	NULL
protein	NULL
or	NULL
other	NULL
similarly	NULL
mutant	NULL
myogenic	NULL
factors	NULL
,	NULL
might	NULL
initiate	NULL
or	NULL
contribute	NULL
to	NULL
the	NULL
neoplastic	NULL
phenotype	NULL
.	NULL

To	NULL
test	NULL
this	NULL
idea	NULL
,	NULL
we	NULL
have	NULL
surveyed	NULL
19	NULL
primary	NULL
rhabdomyosarcoma	NULL
tumors	NULL
and	NULL
14	NULL
rhabdomyosarcoma	NULL
cell	NULL
lines	NULL
for	NULL
evidence	NULL
of	NULL
mutation	NULL
in	NULL
the	NULL
basic	NULL
domains	NULL
of	NULL
any	NULL
of	NULL
the	NULL
four	NULL
known	NULL
myogenic	NULL
proteins	NULL
.	NULL

We	NULL
used	NULL
PCR	NULL
to	NULL
amplify	NULL
the	NULL
DNA	NULL
binding	NULL
domains	NULL
of	NULL
each	NULL
of	NULL
the	NULL
four	NULL
known	NULL
myogenic	NULL
factors	NULL
and	NULL
subjected	NULL
these	NULL
to	NULL
single-strand	NULL
conformation	NULL
polymorphism	NULL
(	NULL
SSCP	NULL
)	NULL
analysis	NULL
to	NULL
detect	NULL
point	NULL
mutations	NULL
.	NULL

SSCP	NULL
has	NULL
proven	NULL
to	NULL
be	NULL
a	NULL
highly	NULL
sensitive	NULL
and	NULL
reliable	NULL
means	NULL
of	NULL
detecting	NULL
such	NULL
mutations	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
(	NULL
23-25	NULL
)	NULL
.	NULL

In	NULL
our	NULL
survey	NULL
we	NULL
have	NULL
not	NULL
detected	NULL
any	NULL
differences	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
fragments	NULL
obtained	NULL
from	NULL
the	NULL
various	NULL
tumors	NULL
or	NULL
cell	NULL
lines	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
generation	NULL
of	NULL
rhabdomyosarcomas	NULL
is	NULL
not	NULL
commonly	NULL
associated	NULL
with	NULL
the	NULL
acquisition	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
domains	NULL
of	NULL
any	NULL
of	NULL
the	NULL
known	NULL
myogenic	NULL
factors	NULL
.	NULL

Other	NULL
molecular	NULL
events	NULL
are	NULL
more	NULL
likely	NULL
to	NULL
contribute	NULL
to	NULL
the	NULL
sustained	NULL
proliferative	NULL
capacity	NULL
and	NULL
loss	NULL
of	NULL
differentiated	NULL
phenotype	NULL
of	NULL
these	NULL
highly	NULL
aggressive	NULL
childhood	NULL
tumors	NULL
.	NULL

Methods	NULL
Tumor	NULL
tissue	NULL
samples	NULL
.	NULL

19	NULL
primary	NULL
tumors	NULL
(	NULL
13	NULL
embryonal	NULL
,	NULL
6	NULL
alveolar	NULL
)	NULL
and	NULL
the	NULL
following	NULL
14	NULL
cell	NULL
lines	NULL
(	NULL
7	NULL
embryonal	NULL
,	NULL
6	NULL
alveolar	NULL
,	NULL
1	NULL
undifferen-tiated	NULL
)	NULL
were	NULL
studied	NULL
:	NULL
Rh1	NULL
,	NULL
Rh3	NULL
,	NULL
Rh4	NULL
,	NULL
Rh5	NULL
,	NULL
Rh18	NULL
,	NULL
Rh30	NULL
,	NULL
SA2	NULL
,	NULL
AD2	NULL
,	NULL
Rh28	NULL
,	NULL
NIH	NULL
,	NULL
A673	NULL
,	NULL
A204	NULL
,	NULL
TC206C	NULL
,	NULL
and	NULL
MCRB-1	NULL
(	NULL
26-29	NULL
)	NULL
.	NULL

Histopatho-logical	NULL
classification	NULL
was	NULL
in	NULL
accord	NULL
with	NULL
the	NULL
guidelines	NULL
proposed	NULL
by	NULL
Patton	NULL
and	NULL
Horn	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Tumor	NULL
tissue	NULL
samples	NULL
were	NULL
collected	NULL
from	NULL
surgical	NULL
specimens	NULL
and	NULL
snap	NULL
frozen	NULL
and	NULL
stored	NULL
under	NULL
liquid	NULL
nitrogen	NULL
until	NULL
further	NULL
processing	NULL
.	NULL

Peripheral	NULL
leukocytes	NULL
were	NULL
obtained	NULL
from	NULL
10	NULL
healthy	NULL
volunteers	NULL
and	NULL
separated	NULL
from	NULL
other	NULL
blood	NULL
components	NULL
by	NULL
Ficoll-Hypaque	NULL
sedimentation	NULL
.	NULL

Genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
from	NULL
these	NULL
tissues	NULL
by	NULL
standard	NULL
procedures	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Primers	NULL
for	NULL
PCR	NULL
amplification	NULL
.	NULL

The	NULL
forward	NULL
primers	NULL
used	NULL
to	NULL
specifically	NULL
amplify	NULL
MyoD	NULL
,	NULL
myogenin	NULL
,	NULL
myf5	NULL
,	NULL
and	NULL
myf6	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
the	NULL
lengths	NULL
of	NULL
the	NULL
fragments	NULL
amplified	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
Myo	NULL
D	NULL
,	NULL
*	NULL
``	NULL
CTGTGG-GCCTGCAAGGCGTGCAAG**	NULL
:	NULL
167	NULL
bp	NULL
;	NULL
myogenin	NULL
,	NULL
GCCGGA-TCC*	NULL
``	NULL
*TGTAAGAGGAAGTCGGTGTCCGTG®*	NULL
'	NULL
:	NULL
154	NULL
bp	NULL
;	NULL
Myf	NULL
,	NULL
GCCGGATCC*®AAGAGGAAGTCCACCACCATG**	NULL
:	NULL
157	NULL
bp	NULL
;	NULL
Myfé6	NULL
,	NULL
GCCGGATCC*°AAGAGAAAATCTGCCCCCACTG**	NULL
:	NULL
156	NULL
bp	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
myogenin	NULL
,	NULL
myf5	NULL
,	NULL
and	NULL
myf6	NULL
,	NULL
BamHI	NULL
sites	NULL
and	NULL
``	NULL
G-C	NULL
``	NULL
clamps	NULL
were	NULL
added	NULL
to	NULL
the	NULL
forward	NULL
primers	NULL
to	NULL
facilitate	NULL
cloning	NULL
.	NULL

The	NULL
following	NULL
reverse	NULL
PCR	NULL
primer	NULL
was	NULL
chosen	NULL
for	NULL
all	NULL
four	NULL
myogenic	NULL
genes	NULL
that	NULL
bear	NULL
identical	NULL
sequences	NULL
at	NULL
this	NULL
site	NULL
:	NULL
5°	NULL
GCCAAGCTT	NULL
CACCTT-GGGCAACCGCTGGTTTGG	NULL
.	NULL

A	NULL
HindIII	NULL
site	NULL
and	NULL
``	NULL
G-C	NULL
``	NULL
clamp	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reverse	NULL
primer	NULL
.	NULL

The	NULL
following	NULL
primers	NULL
were	NULL
used	NULL
to	NULL
amplify	NULL
a	NULL
159-bp	NULL
fragment	NULL
containing	NULL
the	NULL
murine	NULL
MyoD	NULL
basic	NULL
domain	NULL
from	NULL
plasmid	NULL
DNAs	NULL
:	NULL
Fwd	NULL
:	NULL
***CTGTGGGCCRFCAAGGCGTGCAAG	NULL
;	NULL
Rev	NULL
:	NULL
CCGAACCAG-CGGCTACCCAAGGTG®**	NULL
.	NULL

PCR	NULL
amplification	NULL
and	NULL
fragment	NULL
isolation	NULL
.	NULL

For	NULL
plasmid	NULL
DNA	NULL
amplification	NULL
,	NULL
we	NULL
chose	NULL
several	NULL
MyoD	NULL
cDNAs	NULL
in	NULL
which	NULL
we	NULL
had	NULL
previously	NULL
introduced	NULL
specific	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
basic	NULL
domains	NULL
(	NULL
22	NULL
)	NULL
.	NULL

These	NULL
were	NULL
used	NULL
to	NULL
establish	NULL
that	NULL
the	NULL
conditions	NULL
chosen	NULL
for	NULL
SSCP	NULL
analysis	NULL
could	NULL
distinguish	NULL
among	NULL
these	NULL
various	NULL
mutants	NULL
and	NULL
the	NULL
wild-type	NULL
MyoD	NULL
cDNA	NULL
sequence	NULL
.	NULL

The	NULL
specific	NULL
MyoD	NULL
plasmid	NULL
DNAs	NULL
chosen	NULL
contained	NULL
the	NULL
following	NULL
mutations	NULL
:	NULL
mutant	NULL
3	NULL
:	NULL
Ala	NULL
;	NULL
,	NULL
,	NULL
»	NULL
Thr	NULL
;	NULL
Mutant	NULL
6	NULL
:	NULL
Met	NULL
,	NULL
,	NULL
>	NULL
»	NULL
Val	NULL
;	NULL
Mutant	NULL
7	NULL
:	NULL
Arg	NULL
,	NULL
,	NULL
,	NULL
-	NULL
»	NULL
Leu	NULL
;	NULL
Mutant	NULL
9	NULL
:	NULL
Leyu	NULL
;	NULL
;	NULL
;	NULL
-+	NULL
»	NULL
Arg	NULL
.	NULL

For	NULL
genomic	NULL
DNA	NULL
amplification	NULL
,	NULL
the	NULL
PCR	NULL
mixture	NULL
contained	NULL
500	NULL
ng	NULL
of	NULL
genomic	NULL
DNA	NULL
,	NULL
1	NULL
pg	NULL
of	NULL
each	NULL
primer	NULL
,	NULL
3.75	NULL
mM	NULL
MgCl	NULL
,	NULL
(	NULL
for	NULL
myogenin	NULL
and	NULL
MyoD	NULL
)	NULL
or	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
(	NULL
for	NULL
myf5	NULL
and	NULL
myf6	NULL
)	NULL
,	NULL
1:10	NULL
reaction	NULL
volume	NULL
of	NULL
magnesium-free	NULL
1I0X	NULL
PCR	NULL
buffer	NULL
(	NULL
Promega	NULL
Biotec	NULL
,	NULL
6	NULL
G.	NULL
Anand	NULL
,	NULL
D.	NULL
N.	NULL
Shapiro	NULL
,	NULL
P.	NULL
S.	NULL
Dickman	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Prochownik	NULL
Madison	NULL
,	NULL
WI	NULL
}	NULL
,	NULL
4	NULL
mM	NULL
each	NULL
of	NULL
dNTP	NULL
,	NULL
5	NULL
uCi	NULL
of	NULL
a-	NULL
[	NULL
P	NULL
]	NULL
JG	NULL
@	NULL
CTP	NULL
(	NULL
sp	NULL
act	NULL
,	NULL
>	NULL
3.000	NULL
Ci/mmol	NULL
;	NULL
Amersham	NULL
,	NULL
Arlington	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
and	NULL
0.5	NULL
U	NULL
of	NULL
Taq	NULL
poly-merase	NULL
in	NULL
a	NULL
25-4l	NULL
reaction	NULL
volume	NULL
.	NULL

Amplification	NULL
was	NULL
performed	NULL
for	NULL
40	NULL
cycles	NULL
with	NULL
denaturation	NULL
at	NULL
94°C	NULL
,	NULL
annealing	NULL
at	NULL
58°C	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
1	NULL
min	NULL
each	NULL
.	NULL

Similar	NULL
conditions	NULL
were	NULL
used	NULL
to	NULL
amplify	NULL
MyoD	NULL
cDNA	NULL
sequences	NULL
except	NULL
that	NULL
the	NULL
PCRs	NULL
contained	NULL
100	NULL
pg	NULL
of	NULL
the	NULL
appropriate	NULL
linearized	NULL
plasmid	NULL
DNA	NULL
.	NULL

Specific	NULL
bands	NULL
were	NULL
excised	NULL
from	NULL
a	NULL
5	NULL
%	NULL
acrylamide	NULL
gel	NULL
,	NULL
incubated	NULL
in	NULL
an	NULL
elution	NULL
buffer	NULL
containing	NULL
0.5	NULL
M	NULL
ammo-nium	NULL
acetate	NULL
,	NULL
0.01	NULL
M	NULL
magnesium	NULL
acetate	NULL
,	NULL
|	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
overnight	NULL
,	NULL
extracted	NULL
with	NULL
phenol	NULL
/chloroform/	NULL
isoamyl	NULL
alcohol	NULL
,	NULL
precipitated	NULL
with	NULL
ethanol	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
distilled	NULL
water	NULL
.	NULL

The	NULL
eluted	NULL
fragments	NULL
migrated	NULL
as	NULL
single	NULL
bands	NULL
upon	NULL
reelectrophoresis	NULL
in	NULL
nondenaturing	NULL
polyacrylamide	NULL
or	NULL
agarose	NULL
gels	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

That	NULL
the	NULL
PCR	NULL
product	NULL
obtained	NULL
derived	NULL
from	NULL
the	NULL
appropriate	NULL
gene	NULL
was	NULL
confirmed	NULL
by	NULL
restriction	NULL
mapping	NULL
and	NULL
,	NULL
in	NULL
select	NULL
cases	NULL
,	NULL
DNA	NULL
sequencing	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

SSCP	NULL
analysis	NULL
.	NULL

SSCP	NULL
analysis	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Approximately	NULL
10,000	NULL
cpm	NULL
of	NULL
the	NULL
purified	NULL
PCR	NULL
fragment	NULL
(	NULL
1	NULL
ul	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
9	NULL
ul	NULL
of	NULL
a	NULL
loading	NULL
dye	NULL
(	NULL
20	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
95	NULL
%	NULL
formamide	NULL
,	NULL
0.04	NULL
%	NULL
xylene	NULL
cyanol	NULL
,	NULL
0.04	NULL
%	NULL
bromophenol	NULL
blue	NULL
)	NULL
,	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
quick	NULL
chilled	NULL
on	NULL
ice	NULL
.	NULL

2.5	NULL
ul	NULL
was	NULL
loaded	NULL
on	NULL
a	NULL
5	NULL
%	NULL
acrylamide	NULL
gel	NULL
containing	NULL
6.25	NULL
%	NULL
glycerol	NULL
and	NULL
electropheresis	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
4°C	NULL
for	NULL
4	NULL
h	NULL
at	NULL
35	NULL
mA	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
under	NULL
vacuum	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
for	NULL
16	NULL
h	NULL
at	NULL
-	NULL
80°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
intensifying	NULL
screen	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
To	NULL
first	NULL
establish	NULL
that	NULL
the	NULL
conditions	NULL
chosen	NULL
for	NULL
SSCP	NULL
analysis	NULL
could	NULL
distinguish	NULL
a	NULL
mutant	NULL
gene	NULL
from	NULL
the	NULL
wild	NULL
type	NULL
,	NULL
we	NULL
used	NULL
several	NULL
plasmids	NULL
that	NULL
encoded	NULL
either	NULL
a	NULL
wild-type	NULL
murine	NULL
MyoD	NULL
cDNA	NULL
or	NULL
the	NULL
same	NULL
cDNA	NULL
with	NULL
individual	NULL
point	NULL
mutations	NULL
deliberately	NULL
engineered	NULL
into	NULL
the	NULL
DNA	NULL
binding	NULL
basic	NULL
domain	NULL
(	NULL
22	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
tested	NULL
,	NULL
DNA	NULL
fragments	NULL
containing	NULL
point	NULL
mutations	NULL
were	NULL
readily	NULL
distinguishable	NULL
from	NULL
the	NULL
wild-type	NULL
sequence	NULL
and	NULL
from	NULL
one	NULL
another	NULL
after	NULL
SSCP	NULL
analysis	NULL
.	NULL

We	NULL
conclude	NULL
from	NULL
these	NULL
experiments	NULL
that	NULL
SSCP	NULL
analysis	NULL
provides	NULL
a	NULL
sensitive	NULL
and	NULL
reliable	NULL
means	NULL
of	NULL
detecting	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
MyoD	NULL
basic	NULL
domain	NULL
.	NULL

We	NULL
next	NULL
analyzed	NULL
genomic	NULL
DNA	NULL
samples	NULL
obtained	NULL
from	NULL
33	NULL
rhabdomyosarcomas	NULL
(	NULL
19	NULL
primary	NULL
tumors	NULL
and	NULL
14	NULL
cell	NULL
lines	NULL
)	NULL
and	NULL
from	NULL
the	NULL
peripheral	NULL
leukocytes	NULL
of	NULL
10	NULL
normal	NULL
individuals	NULL
.	NULL

Myogenin	NULL
:	NULL
D	NULL
RLHJAATLR	NULL
Myf	NULL
5	NULL
:	NULL
p	NULL
K	NULL
K	NULL
Myf	NULL
6	NULL
:	NULL
D	NULL
Myo	NULL
D	NULL
:	NULL
D	NULL
Ro	NULL
K-	NULL
A	NULL
A	NULL
T	NULL
jom	NULL
|R	NULL
E0	NULL
oR	NULL
R	NULL
R	NULL
R	NULL
R	NULL
R	NULL
R	NULL
|R	NULL
No	NULL
Ho	NULL
ON	NULL
lob	NULL
|L	NULL
oB	NULL
or	NULL
L-myc	NULL
:	NULL
T	NULL
R	NULL
}	NULL
Ko	NULL
JN	NULL
OH	NULL
ON	NULL
[	NULL
OF	NULL
iL	NULL
E	NULL
or	NULL
Max	NULL
:	NULL
D	NULL
R	NULL
}	NULL
a	NULL
o	NULL
HoO	NULL
[	NULL
H	NULL
N|	NULL
a	NULL
|L	NULL
oe	NULL
or	NULL
R	NULL
Figure	NULL
1	NULL
.	NULL

Amino	NULL
acid	NULL
(	NULL
aa	NULL
)	NULL
sequence	NULL
comparison	NULL
of	NULL
the	NULL
basic	NULL
domain	NULL
.	NULL

The	NULL
sequences	NULL
compared	NULL
are	NULL
the	NULL
following	NULL
:	NULL
myogenin	NULL
(	NULL
aa	NULL
81-94	NULL
)	NULL
,	NULL
MyoD	NULL
(	NULL
aa	NULL
109-122	NULL
)	NULL
,	NULL
myf5	NULL
(	NULL
aa	NULL
83-96	NULL
)	NULL
,	NULL
myf6	NULL
(	NULL
aa	NULL
93-106	NULL
)	NULL
.	NULL

The	NULL
amino	NULL
acid	NULL
residues	NULL
in	NULL
the	NULL
basic	NULL
region	NULL
that	NULL
were	NULL
changed	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
analogous	NULL
position	NULL
in	NULL
c-myc	NULL
are	NULL
numbered	NULL
from	NULL
1	NULL
through	NULL
9	NULL
.	NULL

Mutant	NULL
9	NULL
where	NULL
Leu	NULL
;	NULL
;	NULL
,	NULL
was	NULL
changed	NULL
to	NULL
Arg	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
astrix	NULL
.	NULL

C-myc	NULL
:	NULL
v	NULL
I	NULL
Z	NULL
<	NULL
t	NULL
m	NULL
x	NULL
[	NULL
e	NULL
_o	NULL
]	NULL
_	NULL
2	NULL
m	NULL
o=	NULL
=	NULL
mmmzﬂ-r-r-rr-u-	NULL
N-myc	NULL
:	NULL
E	NULL
MUT7	NULL
(	NULL
Arg417-	NULL
>	NULL
Leu	NULL
)	NULL
MUTY	NULL
(	NULL
Leu	NULL
{	NULL
22-	NULL
>	NULL
Arg	NULL
)	NULL
MUT3	NULL
(	NULL
Ala	NULL
{	NULL
;	NULL
s-	NULL
>	NULL
Thr	NULL
)	NULL
MUT6	NULL
(	NULL
M0t116—	NULL
)	NULL
V3|	NULL
)	NULL
#	NULL
|	NULL
wild	NULL
Type	NULL
@	NULL
Figure	NULL
2	NULL
.	NULL

Mobility	NULL
shift	NULL
analysis	NULL
of	NULL
murine	NULL
MyoD	NULL
mutants	NULL
.	NULL

DNA	NULL
fragments	NULL
encoding	NULL
the	NULL
basic	NULL
domain	NULL
of	NULL
MyoD	NULL
from	NULL
wild-type	NULL
and	NULL
mutants	NULL
3	NULL
,	NULL
6	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
(	NULL
22	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
SSCP	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

Each	NULL
mutant	NULL
fragment	NULL
migrated	NULL
with	NULL
a	NULL
characteristic	NULL
|	NULL
__	NULL
pattern	NULL
different	NULL
from	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
.	NULL

3	NULL
,	NULL
&	NULL
PCR	NULL
was	NULL
performed	NULL
using	NULL
primers	NULL
specific	NULL
for	NULL
MyoD	NULL
,	NULL
myogen-ein	NULL
,	NULL
myf5	NULL
,	NULL
and	NULL
myf6	NULL
.	NULL

Specific	NULL
amplified	NULL
bands	NULL
were	NULL
obtained	NULL
in	NULL
all	NULL
cases	NULL
and	NULL
were	NULL
subsequently	NULL
purified	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
before	NULL
being	NULL
subjected	NULL
to	NULL
SSCP	NULL
analysis	NULL
.	NULL

The	NULL
myogenic	NULL
gene	NULL
of	NULL
origin	NULL
of	NULL
the	NULL
amplified	NULL
fragment	NULL
was	NULL
confirmed	NULL
by	NULL
establishing	NULL
the	NULL
presence	NULL
of	NULL
predicted	NULL
restriction	NULL
en-donuclease	NULL
sites	NULL
or	NULL
by	NULL
DNA	NULL
sequencing	NULL
of	NULL
selected	NULL
cloned	NULL
fragments	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Under	NULL
our	NULL
experimental	NULL
conditions	NULL
,	NULL
the	NULL
patterns	NULL
of	NULL
DNA	NULL
strand	NULL
migration	NULL
were	NULL
identical	NULL
for	NULL
fragments	NULL
obtained	NULL
from	NULL
either	NULL
normal	NULL
or	NULL
tumor	NULL
DNAs	NULL
,	NULL
suggesting	NULL
identical	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
basic	NULL
domains	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
myogenin	NULL
this	NULL
was	NULL
confirmed	NULL
by	NULL
cloning	NULL
and	NULL
sequencing	NULL
several	NULL
of	NULL
the	NULL
PCR-amplified	NULL
DNA	NULL
fragments	NULL
obtained	NULL
from	NULL
tumor	NULL
DNAs	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
the	NULL
DNA	NULL
sequences	NULL
of	NULL
the	NULL
basic	NULL
Normal	NULL
@	NULL
|	NULL
Tumors	NULL
|	NULL
domains	NULL
corresponded	NULL
to	NULL
the	NULL
previously	NULL
published	NULL
sequence	NULL
(	NULL
32-34	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
we	NULL
found	NULL
no	NULL
evidence	NULL
of	NULL
mutation	NULL
at	NULL
the	NULL
highly	NULL
conserved	NULL
Leu	NULL
that	NULL
corresponds	NULL
to	NULL
Leu	NULL
;	NULL
;	NULL
,	NULL
of	NULL
MyoD	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
can	NULL
conclude	NULL
from	NULL
this	NULL
study	NULL
that	NULL
mutation	NULL
within	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
none	NULL
of	NULL
the	NULL
four	NULL
myogenic	NULL
factors	NULL
discussed	NULL
here	NULL
is	NULL
commonly	NULL
associated	NULL
with	NULL
the	NULL
occurrence	NULL
of	NULL
rhabdomyosarcomas	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
Arg	NULL
;	NULL
,	NULL
,	NULL
of	NULL
c-myc	NULL
is	NULL
a	NULL
critical	NULL
determinant	NULL
of	NULL
inner	NULL
dinucleotide	NULL
(	NULL
CG	NULL
)	NULL
binding	NULL
specificity	NULL
in	NULL
the	NULL
c-myc	NULL
E-box	NULL
recognition	NULL
site	NULL
,	NULL
CACGTG	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

This	NULL
amino	NULL
acid	NULL
,	NULL
highly	NULL
conserved	NULL
among	NULL
myec/max	NULL
family	NULL
members	NULL
,	NULL
corresponds	NULL
to	NULL
the	NULL
equally	NULL
well-conserved	NULL
leucine	NULL
residue	NULL
of	NULL
the	NULL
four	NULL
myogenic	NULL
factors	NULL
(	NULL
Leu	NULL
;	NULL
;	NULL
,	NULL
in	NULL
MyoD	NULL
)	NULL
,	NULL
which	NULL
,	NULL
by	NULL
analogy	NULL
,	NULL
would	NULL
be	NULL
important	NULL
in	NULL
the	NULL
recognition	NULL
of	NULL
the	NULL
CC	NULL
inner	NULL
dinucleotide	NULL
sequence	NULL
in	NULL
the	NULL
MyoD	NULL
binding	NULL
site	NULL
(	NULL
CACCTG	NULL
)	NULL
by	NULL
the	NULL
MyoD-E12/E47	NULL
heterodimer	NULL
.	NULL

Given	NULL
the	NULL
importance	NULL
of	NULL
these	NULL
basic	NULL
domain	NULL
residues	NULL
to	NULL
DNA	NULL
binding	NULL
and	NULL
,	NULL
in	NULL
particular	NULL
,	NULL
to	NULL
the	NULL
profound	NULL
functional	NULL
consequences	NULL
of	NULL
mutation	NULL
at	NULL
these	NULL
sites	NULL
(	NULL
35	NULL
)	NULL
,	NULL
how	NULL
might	NULL
we	NULL
explain	NULL
why	NULL
they	NULL
are	NULL
not	NULL
mutated	NULL
in	NULL
rhabdomyosarcomas	NULL
?	NULL

Perhaps	NULL
the	NULL
simplest	NULL
explanation	NULL
lies	NULL
in	NULL
the	NULL
redundancy	NULL
of	NULL
the	NULL
myogenic	NULL
pathway	NULL
.	NULL

Assuming	NULL
that	NULL
a	NULL
mutation	NULL
such	NULL
as	NULL
the	NULL
MyoD	NULL
Leu	NULL
;	NULL
;	NULL
,	NULL
-	NULL
»	NULL
Arg	NULL
did	NULL
occur	NULL
,	NULL
it	NULL
is	NULL
quite	NULL
conceivable	NULL
that	NULL
its	NULL
effects	NULL
would	NULL
be	NULL
negligible	NULL
due	NULL
to	NULL
its	NULL
competition	NULL
for	NULL
binding	NULL
sites	NULL
,	NULL
not	NULL
only	NULL
with	NULL
wild-type	NULL
MyoD	NULL
encoded	NULL
by	NULL
the	NULL
unmutated	NULL
allele	NULL
but	NULL
with	NULL
the	NULL
other	NULL
myogenic	NULL
factors	NULL
as	NULL
well	NULL
.	NULL

Similarly	NULL
,	NULL
despite	NULL
the	NULL
progressive	NULL
decline	NULL
of	NULL
c-myc	NULL
protein	NULL
levels	NULL
in	NULL
differentiating	NULL
cells	NULL
,	NULL
c-myc	NULL
binding	NULL
sites	NULL
might	NULL
continue	NULL
to	NULL
be	NULL
occupied	NULL
by	NULL
max	NULL
homodimers	NULL
that	NULL
bind	NULL
with	NULL
quite	NULL
high	NULL
affinity	NULL
to	NULL
these	NULL
sites	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Other	NULL
bHLH	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
the	NULL
upstream	NULL
stimulatory	NULL
factor	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
other	NULL
more	NULL
recently	NULL
described	NULL
max	NULL
dimerization	NULL
partners	NULL
,	NULL
such	NULL
as	NULL
mad	NULL
and	NULL
mxi	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
,	NULL
would	NULL
also	NULL
be	NULL
expected	NULL
to	NULL
compete	NULL
with	NULL
mutant	NULL
MyoD	NULL
proteins	NULL
for	NULL
these	NULL
sites	NULL
as	NULL
well	NULL
.	NULL

Under	NULL
such	NULL
conditions	NULL
basic	NULL
region	NULL
mutations	NULL
of	NULL
any	NULL
individual	NULL
myogenic	NULL
protein	NULL
might	NULL
not	NULL
be	NULL
subject	NULL
to	NULL
the	NULL
selective	NULL
pressures	NULL
necessary	NULL
for	NULL
the	NULL
genesis	NULL
of	NULL
a	NULL
rhabdomyosarcoma	NULL
.	NULL

Thus	NULL
,	NULL
one	NULL
additional	NULL
beneficial	NULL
consequence	NULL
of	NULL
bHLH	NULL
family	NULL
redundancy	NULL
might	NULL
be	NULL
to	NULL
guard	NULL
against	NULL
the	NULL
full	NULL
consequences	NULL
of	NULL
such	NULL
deleterious	NULL
mutations	NULL
.	NULL

-	NULL
Tumors	NULL
--	NULL
--	NULL
--	NULL
-	NULL
|	NULL
#	NULL
®	NULL
#	NULL
cguén.ql	NULL
1	NULL
@	NULL
¥	NULL
k	NULL
4C	NULL
wa	NULL
_	NULL
we	NULL
qkﬁﬁyﬂkm	NULL
%	NULL
@	NULL
@	NULL
-	NULL
#	NULL
#	NULL
a	NULL
a	NULL
a	NULL
Figure	NULL
3	NULL
.	NULL

Representative	NULL
SSCP	NULL
analysis	NULL
of	NULL
myogenin	NULL
,	NULL
MyoD	NULL
,	NULL
myf5	NULL
,	NULL
and	NULL
myf6	NULL
DNA	NULL
fragments	NULL
.	NULL

Genomic	NULL
DNA	NULL
from	NULL
either	NULL
normal	NULL
or	NULL
tumor	NULL
tissue	NULL
were	NULL
amplified	NULL
by	NULL
PCR	NULL
with	NULL
%	NULL
~	NULL
@	NULL
&	NULL
#	NULL
Tumors	NULL
Normal	NULL
J	NULL
Normal	NULL
@	NULL
primers	NULL
specific	NULL
for	NULL
each	NULL
of	NULL
the	NULL
myogenic	NULL
genes	NULL
and	NULL
subjected	NULL
to	NULL
SSCP	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

The	NULL
various	NULL
panels	NULL
represent	NULL
Tumors	NULL
.	NULL

.	NULL

samples	NULL
amplified	NULL
with	NULL
primers	NULL
spe-	NULL
IHP	NULL
!	NULL

&	NULL
4	NULL
``	NULL
0	NULL
%	NULL
#	NULL
6	NULL
cific	NULL
for	NULL
the	NULL
following	NULL
order	NULL
of	NULL
genes	NULL
:	NULL
(	NULL
A	NULL
)	NULL
myogenin	NULL
,	NULL
(	NULL
B	NULL
)	NULL
MyoD	NULL
,	NULL
(	NULL
C	NULL
)	NULL
myf5	NULL
,	NULL
and	NULL
(	NULL
D	NULL
)	NULL
myf6	NULL
.	NULL

There	NULL
appears	NULL
to	NULL
be	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
migratory	NULL
pattern	NULL
between	NULL
the	NULL
normal	NULL
and	NULL
tumor	NULL
DNA	NULL
for	NULL
all	NULL
the	NULL
genes	NULL
analyzed	NULL
.	NULL

Basic	NULL
Domain	NULL
of	NULL
Myogenic	NULL
Factors	NULL
in	NULL
Rhabdomyosarcoma	NULL
7	NULL
At	NULL
least	NULL
two	NULL
additional	NULL
factors	NULL
might	NULL
conspire	NULL
against	NULL
the	NULL
selection	NULL
of	NULL
``	NULL
activating	NULL
``	NULL
mutations	NULL
within	NULL
the	NULL
basic	NULL
regions	NULL
of	NULL
myogenic	NULL
genes	NULL
.	NULL

One	NULL
of	NULL
these	NULL
is	NULL
the	NULL
apparent	NULL
absence	NULL
in	NULL
rhabdomyosarcomas	NULL
of	NULL
one	NULL
or	NULL
more	NULL
accessory	NULL
molecules	NULL
necessary	NULL
for	NULL
the	NULL
function	NULL
of	NULL
the	NULL
MyoD	NULL
transactivation	NULL
domain	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
a	NULL
myogenically	NULL
conducive	NULL
environment	NULL
might	NULL
explain	NULL
why	NULL
neither	NULL
endogenous	NULL
myogenic	NULL
proteins	NULL
,	NULL
commonly	NULL
expressed	NULL
in	NULL
rhabdomyosarcomas	NULL
,	NULL
nor	NULL
those	NULL
driven	NULL
by	NULL
trans-fected	NULL
expression	NULL
vectors	NULL
,	NULL
significantly	NULL
alter	NULL
the	NULL
transformed	NULL
phenotype	NULL
of	NULL
such	NULL
tumors	NULL
(	NULL
43	NULL
)	NULL
.	NULL

The	NULL
second	NULL
factor	NULL
that	NULL
might	NULL
select	NULL
against	NULL
the	NULL
generation	NULL
of	NULL
activating	NULL
mutations	NULL
is	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
transactivating	NULL
domains	NULL
of	NULL
the	NULL
myogenic	NULL
proteins	NULL
themselves	NULL
.	NULL

Although	NULL
the	NULL
MyoD	NULL
Leu	NULL
;	NULL
;	NULL
,	NULL
>	NULL
»	NULL
Arg	NULL
mutation	NULL
does	NULL
indeed	NULL
mimic	NULL
c-myc	NULL
in	NULL
terms	NULL
of	NULL
its	NULL
ability	NULL
to	NULL
regulate	NULL
a	NULL
c-myc-responsive	NULL
gene	NULL
,	NULL
this	NULL
effect	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
universal	NULL
.	NULL

Other	NULL
accessory	NULL
proteins	NULL
that	NULL
interact	NULL
specifically	NULL
with	NULL
the	NULL
c-myc	NULL
transactivation	NULL
domain	NULL
may	NULL
be	NULL
essential	NULL
for	NULL
the	NULL
proper	NULL
regulation	NULL
of	NULL
target	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
transformation	NULL
pathway	NULL
.	NULL

Mutant	NULL
myogenic	NULL
proteins	NULL
with	NULL
the	NULL
capacity	NULL
to	NULL
bind	NULL
c-myc	NULL
sites	NULL
might	NULL
not	NULL
necessarily	NULL
interact	NULL
with	NULL
the	NULL
accessory	NULL
factors	NULL
required	NULL
for	NULL
subsequent	NULL
transcriptional	NULL
control	NULL
of	NULL
all	NULL
c-myc	NULL
regulated	NULL
genes	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
notion	NULL
is	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
mutant	NULL
MyoD	NULL
protein	NULL
to	NULL
transform	NULL
susceptible	NULL
rat	NULL
embryo	NULL
cells	NULL
in	NULL
conjunction	NULL
with	NULL
an	NULL
activated	NULL
ras	NULL
oncogene	NULL
(	NULL
our	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
mutations	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
domains	NULL
of	NULL
four	NULL
myogenic	NULL
proteins	NULL
do	NULL
not	NULL
occur	NULL
with	NULL
any	NULL
appreciable	NULL
frequency	NULL
in	NULL
rhabdomyosarcomas	NULL
.	NULL

Such	NULL
mutations	NULL
may	NULL
be	NULL
selected	NULL
against	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
redundancy	NULL
of	NULL
the	NULL
myogenic	NULL
and	NULL
c-myc	NULL
pathways	NULL
,	NULL
an	NULL
intracellular	NULL
environment	NULL
that	NULL
prevents	NULL
the	NULL
proper	NULL
function	NULL
of	NULL
the	NULL
transcriptional	NULL
activation	NULL
domains	NULL
of	NULL
the	NULL
myogenic	NULL
proteins	NULL
,	NULL
or	NULL
lack	NULL
of	NULL
binding	NULL
of	NULL
accessory	NULL
proteins	NULL
necessary	NULL
for	NULL
the	NULL
proper	NULL
regulation	NULL
of	NULL
c-myc-responsive	NULL
genes	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
John	NULL
Law	NULL
for	NULL
providing	NULL
the	NULL
tumor	NULL
DNA	NULL
samples	NULL
and	NULL
Selma	NULL
Siege	NULL
!	NULL

for	NULL
helpful	NULL
discussions	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
HL-33741	NULL
to	NULL
E.	NULL
V.	NULL
Prochownik	NULL
,	NULL
and	NULL
NIH	NULL
grant	NULL
CA-23099	NULL
,	NULL
Institutional	NULL
Cancer	NULL
Center	NULL
CORE	NULL
grant	NULL
CA-21765	NULL
,	NULL
and	NULL
American	NULL
Lebanese	NULL
Syrian	NULL
Associated	NULL
Charities	NULL
to	NULL
D.	NULL
N.	NULL
Shapiro	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Emerson	NULL
,	NULL
C.	NULL
P.	NULL
1990	NULL
.	NULL

Myogenin	NULL
and	NULL
myogenic	NULL
control	NULL
genes	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

21065-1075	NULL
.	NULL

2	NULL
.	NULL

Weintraub	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
Davis	NULL
,	NULL
S.	NULL
Tapscott	NULL
,	NULL
M.	NULL
Thayer	NULL
,	NULL
M.	NULL
Krause	NULL
,	NULL
R.	NULL
Benezra	NULL
,	NULL
T.	NULL
K.	NULL
Blackwell	NULL
,	NULL
D.	NULL
Turner	NULL
,	NULL
R.	NULL
Rupp	NULL
,	NULL
S.	NULL
Hollenberg	NULL
,	NULL
Y.	NULL
Zhuang	NULL
,	NULL
and	NULL
A.	NULL
Lassar	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
myoD	NULL
gene	NULL
family	NULL
:	NULL
nodal	NULL
point	NULL
during	NULL
specification	NULL
of	NULL
the	NULL
muscle	NULL
cell	NULL
lineage	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

251:761-766	NULL
.	NULL

3	NULL
.	NULL

Wright	NULL
,	NULL
W.	NULL
E.	NULL
1992	NULL
.	NULL

Muscle	NULL
basic	NULL
helix-loop-helix	NULL
proteins	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
myogenesis	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genetic	NULL
Development	NULL
.	NULL

2:243-248	NULL
.	NULL

4	NULL
.	NULL

Davis	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
P.	NULL
F.	NULL
Cheng	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Lassar	NULL
,	NULL
and	NULL
H.	NULL
Weintraub	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
myoD	NULL
DNA	NULL
binding	NULL
domain	NULL
contains	NULL
a	NULL
recognition	NULL
code	NULL
for	NULL
muscle-specific	NULL
gene	NULL
acti-vation	NULL
.	NULL

Cell	NULL
60:733-746	NULL
.	NULL

5	NULL
.	NULL

Brennan	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
T.	NULL
Chakraborty	NULL
,	NULL
and	NULL
E.	NULL
N.	NULL
Olson	NULL
.	NULL

1991	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
myogenin	NULL
basic	NULL
region	NULL
identifies	NULL
an	NULL
ancient	NULL
protein	NULL
motif	NULL
critical	NULL
for	NULL
activation	NULL
of	NULL
myogenesis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:5675-5679	NULL
.	NULL

6	NULL
.	NULL

Winter	NULL
,	NULL
B.	NULL
,	NULL
T.	NULL
Braun	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Arnold	NULL
.	NULL

1992	NULL
.	NULL

Co-operativity	NULL
of	NULL
functional	NULL
domains	NULL
in	NULL
the	NULL
muscle-specific	NULL
transcription	NULL
factor	NULL
Myf-5	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

11:1843-1855	NULL
.	NULL

7	NULL
.	NULL

Braun	NULL
,	NULL
T.	NULL
,	NULL
B	NULL
.	NULL

Winter	NULL
,	NULL
E.	NULL
Bober	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Arnold	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
activation	NULL
domain	NULL
of	NULL
the	NULL
muscle-specific	NULL
gene-regulatory	NULL
protein	NULL
myfS5	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

346:663-665	NULL
.	NULL

8	NULL
-	NULL
G.	NULL
Anand	NULL
,	NULL
D.	NULL
N.	NULL
Shapiro	NULL
,	NULL
P.	NULL
S.	NULL
Dickman	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Prochownik	NULL
8	NULL
.	NULL

Sassoon	NULL
,	NULL
D.	NULL
,	NULL
G.	NULL
Lyons	NULL
,	NULL
W.	NULL
E.	NULL
Wright	NULL
,	NULL
V.	NULL
Lin	NULL
,	NULL
A.	NULL
Lassar	NULL
,	NULL
H.	NULL
Weintraub	NULL
,	NULL
and	NULL
M.	NULL
Buckingham	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
two	NULL
myogenic	NULL
regulatory	NULL
factors	NULL
myogenin	NULL
and	NULL
MyoD1	NULL
during	NULL
mouse	NULL
embryogenesis	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

341:303-307	NULL
.	NULL

9	NULL
.	NULL

Bober	NULL
,	NULL
E.	NULL
,	NULL
G.	NULL
E.	NULL
Lyons	NULL
,	NULL
T.	NULL
Braun	NULL
,	NULL
G.	NULL
Cossu	NULL
,	NULL
M.	NULL
Buckingham	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Arnold	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
muscle	NULL
regulatory	NULL
gene	NULL
,	NULL
Myf-6	NULL
,	NULL
has	NULL
a	NULL
biphasic	NULL
pattern	NULL
of	NULL
expression	NULL
during	NULL
early	NULL
mouse	NULL
development	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

113:1255-1265	NULL
.	NULL

10	NULL
.	NULL

Yutzey	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
S.	NULL
J.	NULL
Rhodes	NULL
,	NULL
and	NULL
S.	NULL
F.	NULL
Konieczny	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
trans	NULL
activation	NULL
associated	NULL
with	NULL
the	NULL
muscle	NULL
regulatory	NULL
factors	NULL
MyoD1	NULL
,	NULL
myogenin	NULL
and	NULL
MRF4	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:3934-3944	NULL
.	NULL

11	NULL
.	NULL

Tapscott	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
R.	NULL
L.	NULL
Davis	NULL
,	NULL
M.	NULL
J.	NULL
Thayer	NULL
,	NULL
P.	NULL
F.	NULL
Cheng	NULL
,	NULL
H.	NULL
Weintraub	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Lassar	NULL
.	NULL

1988	NULL
.	NULL

MyoD	NULL
:	NULL
a	NULL
nuclear	NULL
phosphoprotein	NULL
requiring	NULL
a	NULL
myc-homology	NULL
region	NULL
to	NULL
convert	NULL
fibroblasts	NULL
to	NULL
myoblasts	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

242:405-411	NULL
.	NULL

12	NULL
.	NULL

Rudnicki	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
T.	NULL
Braun	NULL
,	NULL
S.	NULL
Hinuma	NULL
,	NULL
and	NULL
R.	NULL
Jaenisch	NULL
.	NULL

1992	NULL
.	NULL

Inactivation	NULL
of	NULL
MyoD	NULL
in	NULL
mice	NULL
lead	NULL
to	NULL
up-regulation	NULL
of	NULL
the	NULL
myogenic	NULL
HLH	NULL
gene	NULL
MyfS	NULL
and	NULL
results	NULL
in	NULL
apparently	NULL
normal	NULL
muscle	NULL
development	NULL
.	NULL

Cel/	NULL
.	NULL

71:383-390	NULL
.	NULL

13	NULL
.	NULL

Braun	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
A.	NULL
Rudnicki	NULL
,	NULL
H.	NULL
H.	NULL
Arnold	NULL
,	NULL
and	NULL
R.	NULL
Jaenisch	NULL
.	NULL

1992	NULL
.	NULL

Targeted	NULL
inactivation	NULL
of	NULL
the	NULL
muscle	NULL
regulatory	NULL
gene	NULL
myf-5	NULL
results	NULL
in	NULL
abnormal	NULL
rib	NULL
development	NULL
and	NULL
perinatal	NULL
death	NULL
.	NULL

Cell	NULL
.	NULL

71:369-382	NULL
.	NULL

14	NULL
.	NULL

Lassar	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
R.	NULL
L.	NULL
Davis	NULL
,	NULL
W.	NULL
E.	NULL
Wright	NULL
,	NULL
T.	NULL
Kadesch	NULL
,	NULL
C.	NULL
Murre	NULL
,	NULL
A.	NULL
Voron-ova	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
H.	NULL
Weintraub	NULL
.	NULL

1991	NULL
.	NULL

Functional	NULL
activity	NULL
of	NULL
myogenic	NULL
HLH	NULL
proteins	NULL
require	NULL
hetero-oligomerization	NULL
with	NULL
E12/E47-like	NULL
protein	NULL
in	NULL
vivo	NULL
.	NULL

Cell	NULL
.	NULL

66:305-315	NULL
.	NULL

15	NULL
.	NULL

Blackwell	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
and	NULL
H.	NULL
Weintraub	NULL
.	NULL

1990	NULL
.	NULL

Differences	NULL
and	NULL
similarities	NULL
in	NULL
DNA-binding	NULL
preferences	NULL
of	NULL
MyoD	NULL
and	NULL
E2A	NULL
protein	NULL
complexes	NULL
revealed	NULL
by	NULL
binding	NULL
site	NULL
selection	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

250	NULL
:	NULL
1104-1110	NULL
.	NULL

16	NULL
.	NULL

Blackwood	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
R.	NULL
N.	NULL
Eisenman	NULL
.	NULL

1991	NULL
.	NULL

Max	NULL
:	NULL
a	NULL
helix-loop-helix	NULL
zipper	NULL
protein	NULL
that	NULL
forms	NULL
a	NULL
sequence-specific	NULL
DNA-binding	NULL
complex	NULL
with	NULL
myc	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

251	NULL
:	NULL
1211-1217	NULL
.	NULL

17	NULL
.	NULL

Prendergast	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
D.	NULL
Lawe	NULL
,	NULL
and	NULL
E.	NULL
B.	NULL
Ziff	NULL
.	NULL

1991	NULL
.	NULL

Association	NULL
of	NULL
Myn	NULL
,	NULL
the	NULL
murine	NULL
homolog	NULL
of	NULL
max	NULL
,	NULL
with	NULL
c-myc	NULL
stimulates	NULL
methylation-sensitive	NULL
DNA	NULL
binding	NULL
and	NULL
ras	NULL
cotransformation	NULL
.	NULL

Cell	NULL
.	NULL

65:395-407	NULL
.	NULL

18	NULL
.	NULL

Falcone	NULL
,	NULL
G.	NULL
,	NULL
F.	NULL
Tato	NULL
,	NULL
and	NULL
S.	NULL
Alema	NULL
.	NULL

1985	NULL
.	NULL

Distinctive	NULL
effects	NULL
of	NULL
the	NULL
viral	NULL
oncogenes	NULL
myc	NULL
,	NULL
erb	NULL
,	NULL
fps	NULL
and	NULL
src	NULL
on	NULL
the	NULL
differentiation	NULL
program	NULL
of	NULL
quail	NULL
myogenic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

82:426-430	NULL
.	NULL

19	NULL
.	NULL

Schneider	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
M.	NULL
B.	NULL
Perryman	NULL
,	NULL
P.	NULL
A.	NULL
Payne	NULL
,	NULL
G.	NULL
Spizz	NULL
,	NULL
R.	NULL
Roberts	NULL
,	NULL
and	NULL
E.	NULL
N.	NULL
Olson	NULL
.	NULL

1987	NULL
.	NULL

Autonomous	NULL
expression	NULL
of	NULL
c-myc	NULL
in	NULL
BC	NULL
;	NULL
H1	NULL
cells	NULL
partially	NULL
inhibits	NULL
but	NULL
does	NULL
not	NULL
prevent	NULL
myogenic	NULL
differentiation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:1973-1977	NULL
.	NULL

20	NULL
.	NULL

Sorrentino	NULL
,	NULL
V.	NULL
,	NULL
R.	NULL
Pepperkok	NULL
,	NULL
R.	NULL
L.	NULL
Davis	NULL
,	NULL
W.	NULL
Ansorge	NULL
,	NULL
and	NULL
L.	NULL
Philipson	NULL
.	NULL

1990	NULL
.	NULL

Cell	NULL
proliferation	NULL
inhibited	NULL
by	NULL
MyoD1	NULL
independently	NULL
of	NULL
myogenic	NULL
differentiation	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

345:8	NULL
13-815	NULL
.	NULL

21	NULL
.	NULL

Miner	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
B.	NULL
L.	NULL
Wold	NULL
.	NULL

1991	NULL
.	NULL

C-myc	NULL
inhibition	NULL
of	NULL
MyoD	NULL
and	NULL
myogenin-initiated	NULL
myogenic	NULL
differentiation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:2842-2851	NULL
.	NULL

22	NULL
.	NULL

Van	NULL
Antwerp	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
D.	NULL
G.	NULL
Chen	NULL
,	NULL
C.	NULL
Chang	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Prochownik	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
MyoD	NULL
basic	NULL
domain	NULL
imparts	NULL
c-Myc	NULL
like	NULL
properties	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

89:9010-9014	NULL
.	NULL

23	NULL
.	NULL

Orita	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
H.	NULL
Iwahana	NULL
,	NULL
H.	NULL
Kanazawa	NULL
,	NULL
K.	NULL
Hayashi	NULL
,	NULL
and	NULL
T.	NULL
Sekiya	NULL
.	NULL

1989	NULL
.	NULL

Detection	NULL
of	NULL
polymorphisms	NULL
of	NULL
human	NULL
DNA	NULL
by	NULL
gel	NULL
electrophoresis	NULL
as	NULL
single-strand	NULL
conformation	NULL
polymorphisms	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:2766-2770	NULL
.	NULL

24	NULL
.	NULL

Labrune	NULL
,	NULL
P.	NULL
,	NULL
D.	NULL
Melle	NULL
,	NULL
F.	NULL
Rey	NULL
,	NULL
M.	NULL
Berthelon	NULL
,	NULL
C.	NULL
Caillaud	NULL
,	NULL
R.	NULL
Rey	NULL
,	NULL
A.	NULL
Munnich	NULL
,	NULL
and	NULL
S.	NULL
Lyonnet	NULL
.	NULL

1991	NULL
.	NULL

Single-strand	NULL
conformation	NULL
polymorphism	NULL
for	NULL
detection	NULL
of	NULL
mutation	NULL
and	NULL
base	NULL
substitutions	NULL
in	NULL
phenylketonuria	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Hum	NULL
.	NULL

Genet	NULL
.	NULL

48	NULL
:	NULL
1115-1120	NULL
.	NULL

25	NULL
.	NULL

Ptacek	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
A.	NULL
L.	NULL
George	NULL
,	NULL
Jr.	NULL
,	NULL
R.	NULL
C.	NULL
Griggs	NULL
,	NULL
R.	NULL
Tawii	NULL
,	NULL
R.	NULL
G.	NULL
Kallen	NULL
,	NULL
R.	NULL
L.	NULL
Barchi	NULL
,	NULL
M.	NULL
Robertson	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Leppert	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
gene	NULL
causing	NULL
hyperkalemic	NULL
periodic	NULL
paralysis	NULL
.	NULL

Cell	NULL
.	NULL

67:1021-1027	NULL
.	NULL

26	NULL
.	NULL

Douglas	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
M.	NULL
Valentine	NULL
,	NULL
E.	NULL
Etcubanas	NULL
,	NULL
B.	NULL
L.	NULL
Webber	NULL
,	NULL
P.	NULL
J.	NULL
Houghton	NULL
,	NULL
and	NULL
A	NULL
.	NULL

A	NULL
.	NULL

Green	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
specific	NULL
chromosomal	NULL
abnormality	NULL
in	NULL
rhabdomyosarcoma	NULL
.	NULL

Cytogenet	NULL
.	NULL

Cell	NULL
Genet	NULL
.	NULL

45:148-155	NULL
.	NULL

27	NULL
.	NULL

Both	NULL
are	NULL
ATCC	NULL
lines	NULL
.	NULL

1973	NULL
.	NULL

J.	NULL
Nat/	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

S1:1417-1423	NULL
.	NULL

28	NULL
.	NULL

Trent	NULL
,	NULL
J.	NULL
,	NULL
J.	NULL
Casper	NULL
,	NULL
P.	NULL
Meltzer	NULL
,	NULL
F.	NULL
Thompson	NULL
,	NULL
and	NULL
J.	NULL
Fogh	NULL
.	NULL

1985	NULL
.	NULL

Non	NULL
random	NULL
chromosome	NULL
alterations	NULL
in	NULL
rhabdomyosarcoma	NULL
.	NULL

Cancer	NULL
Genet	NULL
.	NULL

Cytogenet	NULL
.	NULL

16:189-197	NULL
.	NULL

29	NULL
.	NULL

Peng	NULL
,	NULL
W.	NULL
,	NULL
T.	NULL
Knutsen	NULL
,	NULL
K.	NULL
Thell	NULL
,	NULL
M.	NULL
E.	NULL
Horowitz	NULL
,	NULL
and	NULL
T.	NULL
Triche	NULL
.	NULL

1992	NULL
.	NULL

Cytogenetic	NULL
studies	NULL
in	NULL
subgroups	NULL
of	NULL
rhabdomyosarcoma	NULL
.	NULL

Genes	NULL
Chromosomes	NULL
&	NULL
Cancer	NULL
.	NULL

5:299-310	NULL
.	NULL

30	NULL
.	NULL

Patton	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Horn	NULL
,	NULL
Jr.	NULL
1963	NULL
.	NULL

Rhabdomyosarcoma	NULL
:	NULL
clinical	NULL
and	NULL
pathological	NULL
features	NULL
and	NULL
comparison	NULL
with	NULL
human	NULL
fetal	NULL
and	NULL
exbryonal	NULL
skeletal	NULL
muscle	NULL
.	NULL

Surgery	NULL
(	NULL
St.	NULL
Louis	NULL
)	NULL
.	NULL

52:572	NULL
.	NULL

31	NULL
.	NULL

Strauss	NULL
,	NULL
W.	NULL
M.	NULL
1990	NULL
.	NULL

Preparation	NULL
of	NULL
genomic	NULL
DNA	NULL
from	NULL
mammalian	NULL
tissue	NULL
.	NULL

/n	NULL
Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
.	NULL

F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
,	NULL
editors	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

2.2.1-2.2.2	NULL
.	NULL

32	NULL
.	NULL

Braun	NULL
,	NULL
T.	NULL
,	NULL
E.	NULL
Bober	NULL
,	NULL
G.	NULL
B.	NULL
Denker	NULL
,	NULL
S.	NULL
Kotz	NULL
,	NULL
K.	NULL
H.	NULL
Grzeschik	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Arnold	NULL
.	NULL

1989	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
myogenic	NULL
determination	NULL
genes	NULL
in	NULL
muscle	NULL
cells	NULL
:	NULL
possible	NULL
auto	NULL
activation	NULL
by	NULL
the	NULL
myf	NULL
gene	NULL
products	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

8:3617-3625	NULL
.	NULL

33	NULL
.	NULL

Braun	NULL
T.	NULL
,	NULL
E.	NULL
Bober	NULL
,	NULL
B	NULL
.	NULL

Winter	NULL
,	NULL
N.	NULL
Rosenthal	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Arnold	NULL
.	NULL

1990	NULL
.	NULL

Myf6	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
family	NULL
of	NULL
myogenic	NULL
determination	NULL
factors	NULL
:	NULL
evidence	NULL
for	NULL
a	NULL
gene	NULL
cluster	NULL
on	NULL
chromosome	NULL
12	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

9:821-831	NULL
.	NULL

34	NULL
.	NULL

Braun	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
B.	NULL
Denker	NULL
,	NULL
E.	NULL
Bober	NULL
,	NULL
E.	NULL
Tannich	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Arnold	NULL
,	NULL
H.	NULL
H.	NULL
1989	NULL
.	NULL

A	NULL
novel	NULL
human	NULL
muscle	NULL
factor	NULL
related	NULL
to	NULL
but	NULL
distinct	NULL
from	NULL
MyoD	NULL
!	NULL

induces	NULL
myogenic	NULL
conversion	NULL
in	NULL
10T1/2	NULL
fibroblasts	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

8:701~709	NULL
.	NULL

35	NULL
.	NULL

Prochownik	NULL
,	NULL
E.	NULL
V.	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
VanAntwerp	NULL
.	NULL

1993	NULL
.	NULL

Differential	NULL
patterns	NULL
of	NULL
DNA	NULL
binding	NULL
by	NULL
myc	NULL
and	NULL
max	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Nat/	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

90:960-964	NULL
.	NULL

36	NULL
.	NULL

Dang	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
C.	NULL
Dolde	NULL
,	NULL
M.	NULL
L.	NULL
Gillison	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Kato	NULL
.	NULL

1992	NULL
.	NULL

Discrimination	NULL
between	NULL
related	NULL
DNA	NULL
sites	NULL
by	NULL
a	NULL
single	NULL
amino	NULL
acid	NULL
residue	NULL
of	NULL
myc-related	NULL
basic-helix-loop-helix	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

89:599-602	NULL
.	NULL

37	NULL
.	NULL

Kretzner	NULL
,	NULL
L.	NULL
,	NULL
E.	NULL
M.	NULL
Blackwood	NULL
,	NULL
and	NULL
R.	NULL
N.	NULL
Eisenman	NULL
.	NULL

1992	NULL
.	NULL

Myc	NULL
and	NULL
max	NULL
proteins	NULL
possess	NULL
distinct	NULL
transcriptional	NULL
activities	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

359:426-429	NULL
.	NULL

38	NULL
.	NULL

Littlewood	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
B.	NULL
Amati	NULL
,	NULL
H.	NULL
Land	NULL
,	NULL
and	NULL
G.	NULL
I.	NULL
Evan	NULL
.	NULL

1992	NULL
.	NULL

Max	NULL
and	NULL
c-myc/max	NULL
DNA-binding	NULL
activities	NULL
in	NULL
cell	NULL
extracts	NULL
.	NULL

Oncogene	NULL
.	NULL

7:1783-1792	NULL
.	NULL

39	NULL
.	NULL

Gregor	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
M.	NULL
Sawadago	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
adenovirus	NULL
major	NULL
late	NULL
transcription	NULL
factor	NULL
USF	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
helix-loop-helix	NULL
group	NULL
of	NULL
regulatory	NULL
proteins	NULL
and	NULL
binds	NULL
to	NULL
DNA	NULL
as	NULL
a	NULL
dimer	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

4:1730-1740	NULL
.	NULL

40	NULL
.	NULL

Ayer	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
L.	NULL
Kretzner	NULL
,	NULL
and	NULL
R.	NULL
N.	NULL
Eisenman	NULL
.	NULL

1993	NULL
.	NULL

Mad	NULL
:	NULL
A	NULL
heterodimeric	NULL
partner	NULL
for	NULL
Max	NULL
that	NULL
antagonizes	NULL
myc	NULL
transcriptional	NULL
activity	NULL
.	NULL

Cell	NULL
.	NULL

72:211-222	NULL
.	NULL

41	NULL
.	NULL

Zervos	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
J.	NULL
Gyuris	NULL
,	NULL
and	NULL
R.	NULL
Brent	NULL
.	NULL

1993	NULL
.	NULL

Mxi1	NULL
,	NULL
a	NULL
protein	NULL
that	NULL
specifically	NULL
interacts	NULL
with	NULL
max	NULL
to	NULL
bind	NULL
myc-max	NULL
recognition	NULL
sites	NULL
.	NULL

Cel/	NULL
.	NULL

72:223-232	NULL
.	NULL

42	NULL
.	NULL

Tapscott	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
M.	NULL
J.	NULL
Thayer	NULL
,	NULL
and	NULL
H.	NULL
Weintraub	NULL
.	NULL

1993	NULL
.	NULL

Deficiency	NULL
in	NULL
rhabdomyosarcomas	NULL
of	NULL
a	NULL
factor	NULL
required	NULL
for	NULL
MyoD	NULL
activity	NULL
and	NULL
myogenesis	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

259:1450-1453	NULL
.	NULL

43	NULL
.	NULL

Hiti	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
E.	NULL
Bogenmann	NULL
,	NULL
F.	NULL
Gonzales	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Jones	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
MyoD1	NULL
muscle	NULL
determination	NULL
gene	NULL
defines	NULL
differentiation	NULL
capability	NULL
but	NULL
not	NULL
tumorigenicity	NULL
of	NULL
human	NULL
rhabdomyosarcomas	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

57:4722-	NULL
4730	NULL
.	NULL

Basic	NULL
Domain	NULL
of	NULL
Myogenic	NULL
Factors	NULL
in	NULL
Rhabdomyosarcoma	NULL
_	NULL
9	NULL

